-
A ranar 25 ga Afrilu, 2025, InnoCare Pharma ta sanar da cewa Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta ba da shawarar yin bita kan sabon maganin hana kwayar cutar pan-TRK zurletrectinib (ICP-723) na farko, wanda ya amince da amfani da shi...Kara karantawa»
-
A ranar 25 ga Afrilu, 2025, Innovent Biologics ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta amince da Amfani da Sabbin Magunguna (NDA) don limertinib a matsayin magani na farko ga manya da ke fama da cutar kansar huhu ta hanyar gida ko kuma ta hanyar ƙwayoyin cuta (NSCLC)...Kara karantawa»
-
A ranar 23 ga Afrilu, Penpulimab na Akeso ya sami amincewar Hukumar Abinci da Magunguna da cisplatin ko carboplatin da gemcitabine don maganin farko ga manya da ke fama da cutar kansa ta nasopharyngeal non-keratinizing (NPC). Hukumar FDA ta kuma amince da penpulimab-kcqx a matsayin sin...Kara karantawa»
-
A ranar 16 ga Maris, 2025, Akeso ta sanar da cewa Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta amince da sabuwar kwayar maganin hana PD-1 monoclonal antibody mai suna penpulimab don maganin cutar kansa ta nasopharyngeal mai sake dawowa ko kuma ta metastatic a hade ...Kara karantawa»
-
A ranar 24 ga Afrilu, 2025, GenFleet Therapeutics ta sanar da Hukumar Kula da Abinci da Magunguna ta Amurka (FDA) ta amince da sabon maganin da aka yi amfani da shi (IND) na GFH375/VS-7375, wani maganin hana KRAS G12D (ON/OFF) da aka sha ta baki, don gwajin asibiti don magance marasa lafiya da ke fama da ciwon daji masu ƙarfi waɗanda ke ɗauke da maye gurbin KRAS G12D. Binciken...Kara karantawa»
-
A ranar 17 ga Afrilu, 2025, Hansoh Pharmaceutical ta sanar da cewa maganin da aka samar da kansa na B7-H3 wanda aka yi niyya ga maganin rigakafi (ADC) HS-20093 don allura ya sami izinin shiga cikin maganin da Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta kasar Sin ta ayyana, ...Kara karantawa»
-
A ranar 15 ga Afrilu, 2025, InnoCare Pharma ta sanar da cewa Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta karɓi Sabuwar Amfani da Magunguna (NDA) don sabon ƙarni na pan-TRK inhibitor zurletrectinib (ICP-723) don maganin manya da matasa...Kara karantawa»
-
Kwanan nan, GenFleet ta sanar da sabbin bayanai na mataki na biyu na binciken KROCUS, fulzerasib (GFH925, KRAS G12C inhibitor) tare da haɗin gwiwa da cetuximab don maganin cutar kansar huhu ta farko (NSCLC), a cikin wani taƙaitaccen bayani a cikin ƙaramin gabatarwar baki na Ƙungiyar Ciwon Huhu ta Turai ta 2025...Kara karantawa»
-
PLB1004, wanda kamfanin Beijing Avistone Biotechnology Co., Ltd. ya ƙirƙiro, wani magani ne mai aminci, mai zaɓe sosai, kuma mai inganci wanda ba zai iya jurewa ba, wanda ake amfani da shi wajen magance cutar kansar huhu (NSCLC) wadda ba ta da ƙaramin ƙwayar halitta. A ranar 9 ga Afrilu, 2025, Kamfanin Kayayyakin Lafiya na Ƙasa ya ba da...Kara karantawa»
-
A ranar 13 ga Maris, 2025, babbar mujallar kasa da kasa ta Nature Medicine ta buga gwajin maganin rigakafi na B7-H3 na MediLink wanda ke nufin maganin rigakafi (ADC) YL201 Phase 1/1b. Gwajin ya hada da bangaren karuwar allurai (mataki na 1) da kuma bangaren fadada allurai (mataki na 1b). Jimillar marasa lafiya 312 ne aka yi wa rajista a fadin...Kara karantawa»
-
A ranar 21 ga Maris, 2025, Immunofoco ta sanar da cewa Cibiyar Kimanta Magunguna (CDE) a ƙarƙashin Hukumar Kula da Kayayyakin Lafiya ta Ƙasa (NMPA) a China ta ba da izinin yin amfani da maganin EpCAM mai sarrafa kansa, IMC001, don karo na biyu na bincike...Kara karantawa»
-
A ranar 31 ga Maris, 2025, Innovent Biologics ta sanar da cewa Cibiyar Kimanta Magunguna (CDE) ta Hukumar Kayayyakin Lafiya ta Kasa (NMPA) ta ba da Nadin Breakthrough Therapy (BTD) ga IBI363, wani furotin na haɗin ƙwayoyin cuta na PD-1/IL-2α-bias na farko a cikin aji, a matsayin maganin da ake amfani da shi na...Kara karantawa»
Cibiyar likitanci ta haɗin gwiwa ta Asibitin Ciwon Daji na Beijing